(Reuters) - Shares of India's Sun Pharmaceutical Industries Ltd slumped over 13 percent on Friday to near six-year low, after a media report of a complaint by a whistleblower raised fresh concerns on the drugmaker's corporate governance.
The whistleblower complaint alleges that an Indian pharmaceutical manufacturer Aditya Medisales Ltd had transactions with Suraksha Realty, controlled by Sun Pharma's co-promoter, Sudhir Valia, the report stated.
The transactions took place between 2014 and 2017, and were worth over 58 billion rupees ($814.65 million), it added.
A whistleblower had approached SEBI late last year with a document alleging various irregularities by Sun Pharma, its promoter Dilip Shanghvi and others.
Sun Pharma did not immediately respond to a Reuters request seeking comment.
Shares of the country's largest drugmaker by market value recorded their biggest intra-day percentage drop since May 29, 2017.
Over 31.4 million shares changed hands as of 0453 GMT, around 2.7 times Sun's 30-day trading volume average of 11.7 million shares.
Earlier this month, Sun Pharma had recalled muscle relaxtant vecuronium bromide for injection due to the presence of glass.
($1 = 71.1960 Indian rupees)
(Reporting By Arnab Paul in Bengaluru; Editing by Rashmi Aich)
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)